Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill

Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage To Unlock Millions Of Patients In an interview with CNBC, Ricks said that the new policy will allow Medicare beneficiaries to access obesity drugs "immediately following launch" of the company's highly anticipated experimental weight-loss drug, Orforglipron. With 20 million to 30 million Medicare patients p ...